BACKGROUND AND PURPOSE: Due to their potent bronchodilator properties, beta(2)-adrenoceptor agonists are a mainstay of therapy in asthma. However, the effects of beta(2)-adrenoceptor agonists on inflammation are less clear. Accordingly, we have investigated the effects of beta(2)-adrenoceptor agonists on inflammatory mediator release. EXPERIMENTAL APPROACH: Transcription factor activation, and both release and mRNA expression of IL-6 and IL-8 were examined by luciferase reporter assay, elisa and real-time RT-PCR in bronchial human epithelial BEAS-2B cells or primary human bronchial epithelial cells grown at an air-liquid interface. KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected. These effects were mimicked by other cAMP-elevating agents (PGE(2), forskolin). Enhancement of cytokine release by beta(2)-adrenoceptor agonists also occurred in primary bronchial epithelial cells. Addition of dexamethasone with salmeterol repressed IL-6 and IL-8 release to levels that were similar to the repression achieved in the absence of salmeterol. IL-6 release was enhanced when salmeterol was added before, concurrently or after IL-1beta plus histamine stimulation, whereas IL-8 release was only enhanced by salmeterol addition prior to stimulation. CONCLUSIONS AND IMPLICATIONS: Enhancement of IL-6 and IL-8 release may contribute to the deleterious effects of beta(2)-adrenoceptor agonists in asthma. As increased inflammatory mediator expression is prevented by the addition of glucocorticoid to the beta(2)-adrenoceptor, our data provide further mechanistic support for the use of combination therapies in asthma management.
BACKGROUND AND PURPOSE: Due to their potent bronchodilator properties, beta(2)-adrenoceptor agonists are a mainstay of therapy in asthma. However, the effects of beta(2)-adrenoceptor agonists on inflammation are less clear. Accordingly, we have investigated the effects of beta(2)-adrenoceptor agonists on inflammatory mediator release. EXPERIMENTAL APPROACH: Transcription factor activation, and both release and mRNA expression of IL-6 and IL-8 were examined by luciferase reporter assay, elisa and real-time RT-PCR in bronchial human epithelial BEAS-2B cells or primary human bronchial epithelial cells grown at an air-liquid interface. KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected. These effects were mimicked by other cAMP-elevating agents (PGE(2), forskolin). Enhancement of cytokine release by beta(2)-adrenoceptor agonists also occurred in primary bronchial epithelial cells. Addition of dexamethasone with salmeterol repressed IL-6 and IL-8 release to levels that were similar to the repression achieved in the absence of salmeterol. IL-6 release was enhanced when salmeterol was added before, concurrently or after IL-1beta plus histamine stimulation, whereas IL-8 release was only enhanced by salmeterol addition prior to stimulation. CONCLUSIONS AND IMPLICATIONS: Enhancement of IL-6 and IL-8 release may contribute to the deleterious effects of beta(2)-adrenoceptor agonists in asthma. As increased inflammatory mediator expression is prevented by the addition of glucocorticoid to the beta(2)-adrenoceptor, our data provide further mechanistic support for the use of combination therapies in asthma management.
Authors: Alaina J Ammit; Aili L Lazaar; Carla Irani; Geraldine M O'Neill; Nancy D Gordon; Yassine Amrani; Raymond B Penn; Reynold A Panettieri Journal: Am J Respir Cell Mol Biol Date: 2002-04 Impact factor: 6.914
Authors: Christoph F A Vogel; Eric Sciullo; Sujin Park; Christian Liedtke; Christian Trautwein; Fumio Matsumura Journal: J Biol Chem Date: 2003-12-18 Impact factor: 5.157
Authors: Matthew C Catley; Lisa M Cambridge; Yasuyuki Nasuhara; Kazuhiro Ito; Joanna E Chivers; Andrew Beaton; Neil S Holden; Martin W Bergmann; Peter J Barnes; Robert Newton Journal: J Biol Chem Date: 2004-02-19 Impact factor: 5.157
Authors: Quan Sha; Ai Q Truong-Tran; James R Plitt; Lisa A Beck; Robert P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2004-06-10 Impact factor: 6.914
Authors: Koremu K Meja; Matthew C Catley; Lisa M Cambridge; Peter J Barnes; Hazel Lum; Robert Newton; Mark A Giembycz Journal: J Pharmacol Exp Ther Date: 2004-01-27 Impact factor: 4.030
Authors: Sarah Gerlo; Ron Kooijman; Ilse M Beck; Krzysztof Kolmus; Anneleen Spooren; Guy Haegeman Journal: Cell Mol Life Sci Date: 2011-07-09 Impact factor: 9.261
Authors: A Brito; T Santos; K Herculano; M Miranda; A K Sá; J L Carvalho; R Albertini; H Castro-Faria-Neto; A P Ligeiro-de-Oliveira; Flávio Aimbire Journal: Inflammation Date: 2021-03-17 Impact factor: 4.092
Authors: Md Mostafizur Rahman; Nowshin N Rumzhum; Jonathan C Morris; Andrew R Clark; Nicole M Verrills; Alaina J Ammit Journal: Sci Rep Date: 2015-05-18 Impact factor: 4.379